Changeflow GovPing Pharma & Drug Safety USPTO Patent Granted for Orodispersible Powder ...
Routine Notice Added Final

USPTO Patent Granted for Orodispersible Powder Composition

Favicon for changeflow.com USPTO Patent Grants - Pharma (A61K)
Published
Detected
Email

Summary

The USPTO has granted patent US12582601B2 for an orodispersible powder composition developed by BIOPHARMA SYNERGIES, S.L. The patent covers a specific formulation including an active pharmaceutical ingredient and a synergistic combination of sodium citrate, citric acid, and sucralose, along with its use in stick packs, tablets, and as a medicament.

What changed

The United States Patent and Trademark Office (USPTO) has granted patent US12582601B2 to BIOPHARMA SYNERGIES, S.L. for an orodispersible powder composition. The patent specifically claims a formulation containing an active pharmaceutical ingredient combined with a ternary synergistic blend of sodium citrate, citric acid, and sucralose. The grant also extends to stick packs and tablets incorporating this composition, as well as their therapeutic applications.

This patent grant represents a new intellectual property right for the assignee, potentially impacting market exclusivity for specific drug formulations. While not a regulatory rule imposing obligations on other entities, it signifies a new development in pharmaceutical composition technology. Compliance officers in the pharmaceutical sector should be aware of this patent as it may affect product development, licensing, and freedom-to-operate analyses for similar orodispersible formulations.

Archived snapshot

Mar 25, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Orodispersible powder composition

Grant US12582601B2 Kind: B2 Mar 24, 2026

Assignee

BIOPHARMA SYNERGIES, S.L.

Inventors

Francesc Agell Puig

Abstract

An orodispersible powder composition including an active pharmaceutical ingredient and a ternary synergistic combination of sodium citrate, citric acid and sucralose. It also relates to a stick pack and a tablet including such orodispersible powder composition, and their use as a medicament.

CPC Classifications

A61K 9/0056 A61K 9/145 A61K 9/2018 A61K 45/06

Filing Date

2021-12-21

Application No.

18255675

Claims

14

View original document →

Named provisions

Orodispersible powder composition

Get daily alerts for USPTO Patent Grants - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
March 24th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US12582601B2

Who this affects

Applies to
Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Labeling
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!